Discounted Cash Flow
Axsome Therapeutics, Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
| Dividends | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | — | $-27.2m | $-21.4m | — | $-1.42 |
| 2017 | — | $-28.9m (-6.4%) | $-26.5m (-23.8%) | — | $-1.27 (10.6%) |
| 2018 | — | $-31.0m (-7.0%) | $-30.1m (-13.6%) | — | $-1.15 (9.4%) |
| 2019 | — | $-68.3m (-120.7%) | $-46.4m (-54.2%) | — | $-2.01 (-74.8%) |
| 2020 | — | $-102.9m (-50.6%) | $-78.5m (-69.2%) | — | $-2.77 (-37.8%) |
| 2021 | — | $-130.4m (-26.7%) | $-108.5m (-38.3%) | — | $-3.47 (-25.3%) |
| 2022 | $50.0m | $-187.1m (-43.5%) | $-117.2m (-8.0%) | -374.0% | $-4.60 (-32.6%) |
| 2023 | $270.6m (440.8%) | $-239.2m (-27.8%) | $-145.7m (-24.3%) | -88.4% (76.4%) | $-5.27 (-14.6%) |
| 2024 | $385.7m (42.5%) | $-287.2m (-20.1%) | $-128.7m (11.7%) | -74.5% (15.8%) | $-5.99 (-13.7%) |
| 2025 | $638.5m (65.5%) | $-183.2m (36.2%) | $-93.9m (27.0%) | -28.7% (61.5%) | $-3.68 (38.6%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.